This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ETFs Poised to Benefit from Gene Editing Revolution
by Sweta Jaiswal, FRM
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
by Zacks Equity Research
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
by Zacks Equity Research
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -5.26% and -73.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
Editas (EDIT) Inks Cross Licensing Agreement with BlueRock
by Zacks Equity Research
Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.